Annual EBITDA:
-$106.88M+$24.91M(+18.90%)Summary
- As of today, TARS annual EBITDA is -$106.88 million, with the most recent change of +$24.91 million (+18.90%) on December 31, 2024.
- During the last 3 years, TARS annual EBITDA has fallen by -$93.42 million (-694.07%).
- TARS annual EBITDA is now -7823.05% below its all-time high of -$1.35 million, reached on December 31, 2018.
Performance
TARS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$17.79M+$4.79M(+21.22%)Summary
- As of today, TARS quarterly EBITDA is -$17.79 million, with the most recent change of +$4.79 million (+21.22%) on June 30, 2025.
- Over the past year, TARS quarterly EBITDA has increased by +$13.25 million (+42.68%).
- TARS quarterly EBITDA is now -265.09% below its all-time high of $10.78 million, reached on March 31, 2021.
Performance
TARS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$81.71M+$13.25M(+13.95%)Summary
- As of today, TARS TTM EBITDA is -$81.71 million, with the most recent change of +$13.25 million (+13.95%) on June 30, 2025.
- Over the past year, TARS TTM EBITDA has increased by +$62.52 million (+43.35%).
- TARS TTM EBITDA is now -12993.91% below its all-time high of -$624.00 thousand, reached on September 30, 2019.
Performance
TARS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TARS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +18.9% | +42.7% | +43.4% |
| 3Y3 Years | -694.1% | -248.4% | -46.7% |
| 5Y5 Years | -2408.4% | -448.1% | -394.3% |
TARS EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -694.1% | +18.9% | -38.6% | +56.2% | -37.0% | +43.4% |
| 5Y | 5-Year | -2408.4% | +18.9% | -265.1% | +56.2% | -2325.2% | +43.4% |
| All-Time | All-Time | -7823.1% | +18.9% | -265.1% | +56.2% | >-9999.0% | +43.4% |
TARS EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$17.79M(+21.2%) | -$81.71M(+14.0%) |
| Mar 2025 | - | -$22.59M(-10.1%) | -$94.96M(+11.2%) |
| Dec 2024 | -$106.88M(+18.9%) | -$20.51M(+1.5%) | -$106.88M(+15.8%) |
| Sep 2024 | - | -$20.82M(+32.9%) | -$126.97M(+12.0%) |
| Jun 2024 | - | -$31.04M(+10.1%) | -$144.23M(-0.4%) |
| Mar 2024 | - | -$34.51M(+15.0%) | -$143.64M(-9.0%) |
| Dec 2023 | -$131.79M(-120.7%) | -$40.60M(-6.6%) | -$131.79M(-26.7%) |
| Sep 2023 | - | -$38.08M(-25.0%) | -$104.03M(-18.5%) |
| Jun 2023 | - | -$30.45M(-34.4%) | -$87.79M(-40.6%) |
| Mar 2023 | - | -$22.66M(-76.5%) | -$62.44M(-4.7%) |
| Dec 2022 | -$59.70M | -$12.84M(+41.2%) | -$59.66M(+3.1%) |
| Sep 2022 | - | -$21.84M(-327.6%) | -$61.58M(-10.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$5.11M(+74.3%) | -$55.70M(-29.0%) |
| Mar 2022 | - | -$19.88M(-34.7%) | -$43.19M(-244.7%) |
| Dec 2021 | -$13.46M(+50.0%) | -$14.76M(+7.5%) | -$12.53M(-36.1%) |
| Sep 2021 | - | -$15.96M(-315.4%) | -$9.21M(-173.3%) |
| Jun 2021 | - | $7.41M(-31.3%) | -$3.37M(+76.0%) |
| Mar 2021 | - | $10.78M(+194.2%) | -$14.02M(+47.9%) |
| Dec 2020 | -$26.90M(-531.4%) | -$11.44M(-13.0%) | -$26.90M(-62.7%) |
| Sep 2020 | - | -$10.12M(-211.7%) | -$16.53M(-134.9%) |
| Jun 2020 | - | -$3.25M(-54.4%) | -$7.04M(-85.6%) |
| Mar 2020 | - | -$2.10M(-97.5%) | -$3.79M(-124.5%) |
| Dec 2019 | -$4.26M(-215.9%) | -$1.06M(-70.7%) | -$1.69M(-170.7%) |
| Sep 2019 | - | -$624.00K | -$624.00K |
| Dec 2018 | -$1.35M | - | - |
FAQ
- What is Tarsus Pharmaceuticals, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Tarsus Pharmaceuticals, Inc.?
- What is Tarsus Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Tarsus Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Tarsus Pharmaceuticals, Inc.?
- What is Tarsus Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Tarsus Pharmaceuticals, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Tarsus Pharmaceuticals, Inc.?
- What is Tarsus Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Tarsus Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of TARS is -$106.88M
What is the all-time high annual EBITDA for Tarsus Pharmaceuticals, Inc.?
Tarsus Pharmaceuticals, Inc. all-time high annual EBITDA is -$1.35M
What is Tarsus Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, TARS annual EBITDA has changed by +$24.91M (+18.90%)
What is Tarsus Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of TARS is -$17.79M
What is the all-time high quarterly EBITDA for Tarsus Pharmaceuticals, Inc.?
Tarsus Pharmaceuticals, Inc. all-time high quarterly EBITDA is $10.78M
What is Tarsus Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, TARS quarterly EBITDA has changed by +$13.25M (+42.68%)
What is Tarsus Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of TARS is -$81.71M
What is the all-time high TTM EBITDA for Tarsus Pharmaceuticals, Inc.?
Tarsus Pharmaceuticals, Inc. all-time high TTM EBITDA is -$624.00K
What is Tarsus Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, TARS TTM EBITDA has changed by +$62.52M (+43.35%)